Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Top Penny Stocks To Watch In November 2024

In This Article:

Global markets have experienced significant shifts, with U.S. stocks rallying to record highs following a Republican "red sweep" in the recent elections, sparking hopes for growth and tax reforms. Amid these changes, investors are increasingly seeking opportunities in smaller or newer companies often referred to as penny stocks—a term that may sound outdated but remains relevant today. These stocks can offer growth potential at lower price points, especially when they possess strong financials and solid fundamentals.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.22

MYR351.85M

★★★★★★

Rexit Berhad (KLSE:REXIT)

MYR0.785

MYR136.84M

★★★★★★

Lever Style (SEHK:1346)

HK$0.87

HK$552.27M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.475

MYR2.29B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.765

A$144.95M

★★★★☆☆

Seafco (SET:SEAFCO)

THB2.04

THB1.67B

★★★★★★

LaserBond (ASX:LBL)

A$0.6075

A$72.68M

★★★★★★

Wellcall Holdings Berhad (KLSE:WELLCAL)

MYR1.53

MYR761.86M

★★★★★★

ME Group International (LSE:MEGP)

£2.25

£847.72M

★★★★★★

Supreme (AIM:SUP)

£1.63

£190.08M

★★★★★★

Click here to see the full list of 5,755 stocks from our Penny Stocks screener.

We'll examine a selection from our screener results.

Brii Biosciences

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Brii Biosciences Limited focuses on developing therapies for infectious and central nervous system diseases in China and the United States, with a market cap of approximately HK$789.65 million.

Operations: The company's revenue is derived entirely from its biotechnology segment, amounting to CN¥38.38 million.

Market Cap: HK$789.65M

Brii Biosciences, with a market cap of approximately HK$789.65 million, operates in the biotech sector focusing on infectious and central nervous system diseases. The company is pre-revenue, generating CN¥38.38 million entirely from its biotechnology segment. Despite being unprofitable, Brii has reduced losses by 41.3% annually over the past five years and maintains a sufficient cash runway for more than three years without debt concerns. Recent events include its exclusion from the S&P Global BMI Index and reporting increased net losses for H1 2024 compared to last year, highlighting ongoing financial challenges amidst strategic developments in its pipeline.

SEHK:2137 Financial Position Analysis as at Nov 2024
SEHK:2137 Financial Position Analysis as at Nov 2024

China Health Group

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: China Health Group Limited, with a market cap of HK$344.15 million, operates as an investment holding company focused on the distribution and services of medical equipment and consumables in the People's Republic of China.